Jun 3, 2026 08:30AM
May 31, 2026 08:06AM
May 31, 2026 08:06AM
May 21, 2026 04:38PM
May 6, 2026 06:00PM
May 6, 2026 06:00PM
May 6, 2026 04:02PM Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
May 1, 2026 12:54PM
Apr 21, 2026 11:23AM
Apr 21, 2026 11:23AM
Apr 14, 2026 06:46AM
Apr 13, 2026 10:37AM
Apr 13, 2026 08:02AM
Apr 13, 2026 08:00AM Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
Feb 25, 2026 04:02PM
Jan 8, 2026 08:03AM
Jan 8, 2026 08:00AM
Dec 21, 2025 08:00PM
Nov 5, 2025 04:02PM
Oct 27, 2025 08:01AM
Oct 27, 2025 08:00AM Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
Oct 17, 2025 05:16AM
Oct 16, 2025 08:00PM
Aug 6, 2025 04:02PM
Jul 23, 2025 08:00AM
Jul 23, 2025 08:00AM
Jun 30, 2025 08:07AM
Jun 30, 2025 08:00AM Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
Jun 24, 2025 07:01AM
Jun 24, 2025 07:00AM
Jun 23, 2025 09:01AM
Jun 23, 2025 09:00AM
Apr 9, 2025 05:00AM
Feb 26, 2025 04:02PM
Jan 4, 2025 04:00PM 2025 Biopharma sector outlook
Jan 2, 2025 04:00PM
Jan 2, 2025 12:51PM
Aug 7, 2024 04:05PM
Jul 15, 2024 08:53AM
May 9, 2022 04:02PM
Aug 11, 2021 04:01PM
Mar 2, 2021 04:05PM Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
Mar 2, 2021 04:05PM

322,991 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All